Predict your next investment

Inipharm company logo
HEALTHCARE | Biotechnology
inipharm.com

See what CB Insights has to offer

Founded Year

2018

Stage

Series A | Alive

Total Raised

$63.5M

Last Raised

$35M | 1 yr ago

About Inipharm

Inipharm advances a therapeutic pipeline that addresses severe liver diseases with a focus on the HSD17B13 gene.

Inipharm Headquarter Location

Delaware,

United States

Latest Inipharm News

Inipharm to Present Data Showing Potential of Small Molecule Inhibitors of HSD17B13 to Combat Liver Fibrosis at AASLD’s The Liver Meeting

Oct 5, 2021

October 05, 2021 08:00 AM Eastern Daylight Time BELLEVUE, Wash. & SAN DIEGO--( BUSINESS WIRE )--Inipharm, a biopharmaceutical company focused on discovering and developing therapies for liver and related diseases, today announced that it will be presenting data on the anti-fibrotic effects of one of its small-molecule inhibitors of HSD17B13 in a primary human cell “3D liver-on-a-chip” model of NASH at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place virtually November 12-15, 2021. “HSD17B13 is a target of great interest for a range of severe liver disorders, including NASH, given recent findings that certain variants of the gene are strongly associated with liver protection in these diseases,” said Heather Hsu, Ph.D., chief scientific officer of Inipharm. “In these experiments, our HSD17B13 inhibitor INI-678 showed reduction in key markers of fibrosis in a human liver cell-based 3D liver-on-a-chip model, a model which we believe is well-suited to reflect human liver physiology with respect to HSD17B13.” Abstract Title: Potent and selective small molecule HSD17B13 inhibitor INI-678 improves fibrotic markers in NASH liver-on-a-chip Publication Number: 215 Session Broadcast Date and Time: Monday, November 15, 2021, 3:00 PM Key Findings: INI-678 treatment decreased fibrosis markers aSMA (35.4±7.5%, p<0.0001) and collagen type 1 (42.5±6.4 %, p<0.0001) compared to control in a liver-on-a-chip system containing Kupffer cells, stellate cells, and hepatocytes treated with high fat media. INI-678 inhibits HSD17B13-catalyzed oxidation of multiple substrates with low nM potency. INI-678 does not inhibit the other members of the HSD17B family tested nor enzymes and receptors in an off-target panel. About Inipharm Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm’s lead programs are focused on the highly validated genetic target, HSD17B13. There is extensive, consistent evidence that genetic variants in expression of HSD17B13 protein are associated with significantly lower rates and severity of multiple liver diseases. Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Inipharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inipharm is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Inipharm Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Inipharm Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.